The University of Osaka · 의학
히데타츠 오타니 교수의 연구실은 극히 희귀하고 치명적인 뼈 종양인 혈관내피세포종(CCS)과 소엽세포 sarcoma(SS)를 비롯한 희귀 뼈종양의 분자 기전과 치료 반응 메커니즘을 중심으로 연구를 진행하고 있습니다. 특히, 약물 민감도 기전, 유전자 융합 옹포인자(EWSR1::ATF1)의 에피제네틱 조절 메커니즘, 그리고 장기적 예후에 영향을 미치는 종양 크기와 병행도를 규명하고 있습니다. 또한, 뼈종양 치료 후 합병증으로 나타나는 비정상적 골절(AFF) 및 자가 이식 등 보존적 치료 전략의 장기적 결과에 대해서도 꾸준히 연구하고 있습니다.
표시된 성과는 수집된 데이터 기준으로 산출되며, 일부 차이가 있을 수 있습니다.
CCS is a rare, devastating disease, and our established CCS cell line and xenograft model may be a useful tool for further in-depth investigation and understanding of the drug-sensitivity mechanism.
ECI autografts are a durable option for reconstruction after resection of musculoskeletal tumors and provide good function over more than 15 years. Most graft failures occurred within 5 years of the index surgery. However, composite grafts showed a tendency to fail more than 10 years after the surgery.
Tumor size and grade govern prognosis in surgically-treated localized SS in long-term settings. If adequately treated patients have not developed metastases for 5 years after surgery, the risk of subsequently developing metastases was lower than previously reported.
Curettage and SBS filling had been found to be a reasonable treatment method for CB, which commonly occurs in the epiphysis or apophysis. Radiographic joint degeneration was not uncommon after CB treatment, especially in the talus and proximal humerus.
This study reveals the epigenetic and transcriptional suppression mechanism of the fusion oncogene <i>EWSR1::ATF1</i> in clear cell sarcoma by histone deacetylase inhibitor treatment as well as identifying SOX10 as a transcription factor that regulates <i>EWSR1::ATF1</i> expression.
Atypical femoral fractures (AFFs) are recently observed as a complication of long-term bone-modifying agent (BMA; bisphosphonate or denosumab) therapy for bone metastases. We describe the cases of two women diagnosed with breast cancer who developed incomplete AFF associated with BMAs prescribed for bone metastases. Radiographs of their femurs revealed thickening of the lateral subtrochanteric cortex, and tomosynthesis revealed a visible fracture line in the thickened cortex. They were initially
Our case series suggests that patients with localised synovial sarcoma of the hand may have favourable outcomes. Wide excision or marginal excision, followed by radiation therapy combined with chemotherapy, represent acceptable treatment strategies for synovial sarcoma of the hand. Regional lymph node dissection does not seem to be essential for synovial sarcoma of the hand.
Outani, Hidetatsu MD, PhD; Akita, Hirofumi MD, PhD; Nakai, Takaaki MD, PhD; Takada, Ryoji MD; Imura, Yoshinori MD, PhD; Tanaka, Takaaki MD, PhD; Tamiya, Hironari MD, PhD; Oshima, Kazuya MD, PhD; Takahashi, Hidenori MD, PhD; Ohkawa, Kazuyoshi MD, PhD; Katayama, Kazuhiro MD, PhD; Araki, Nobuhito MD, PhD; Naka, Norifumi MD, PhDAuthor Information
Chondromyxoid fibroma is a rare benign tumor, which is composed of immature myxoid mesenchymal tissue with features of early primitive cartilaginous differentiation, accounting for less than 1% of all primary bone tumors. Chondromyxoid fibromas arising from the ilium are relatively rare. Reports on fluorodeoxyglucose-positron emission tomography (FDG-PET) imaging for chondromyxoid fibroma are limited. We present a case of a chondromyxoid fibroma of the left ilium with fluorodeoxyglucose-positron
Synovial sarcoma (SS), a rare subtype of soft-tissue sarcoma distinguished by expression of the fusion gene SS18-SSX, predominantly affects the extremities of young patients. Existing anticancer drugs have limited efficacy against this malignancy, necessitating the development of innovative therapeutic approaches. Given the established role of SS18-SSX in epigenetic regulation, we focused on bromodomain and extra-terminal domain protein (BET) inhibitors and epigenetic agents. Our investigation o
